DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0090-9556/04/3212-1509-1515$20.00
DMD 32:1509-1515, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicoll-Griffith, D. A.
Right arrow Articles by Silva, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicoll-Griffith, D. A.
Right arrow Articles by Silva, J. M.

USE OF A BENZYLOXY-SUBSTITUTED LACTONE CYCLOOXYGENASE-2 INHIBITOR AS A SELECTIVE FLUORESCENT PROBE FOR CYP3A ACTIVITY IN PRIMARY CULTURED RAT AND HUMAN HEPATOCYTES

Deborah A. Nicoll-Griffith, Nathalie Chauret, Robert Houle, Stephen H. Day, Michelle D'Antoni, and José M. Silva1

Merck Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, Quebec, Canada

The benzyloxy-substituted lactone cyclooxygenase-2 inhibitor DFB [3-[(3,4-difluorobenzyl)oxy]-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one] is metabolized in human and rat liver microsomal incubations and hepatocytes to a fluorescent metabolite, DFH [3-hydroxy-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2(5H)-one]. This process is CYP3A-mediated in both species, as demonstrated by incubations with recombinant CYP3A enzymes and experiments with inhibitory antibodies. Measurement of DFH fluorescence can be used as a rapid readout of CYP3A activity following microsomal or cultured hepatocyte incubations. In rat and human hepatocytes treated with prototypical inducers, the formation of DFH was linear for the first 30 min, with no secondary metabolism of DFH, such as phase II glucuronidation, observed at early time points. Using a panel of four prototypical inducers (phenobarbital, dexamethasone, phenytoin, and rifampicin), the correlation between testosterone 6ß-hydroxylation in cultured human hepatocytes and CYP3A enzyme level in cell lysate was confirmed. DFB debenzylation was then shown to correlate well with testosterone 6ß-hydroxylation in hepatocytes treated with these four inducers. Primary cultured rat and human hepatocyte induction assays were optimized for 24- and 96-well plates, respectively. Controls were established to evaluate whether test compounds demonstrate time-dependent CYP3A inhibition to avoid false negative results. Thus, the use of DFB, a fluorogenic CYP3A-selective probe substrate, affords a fast, efficient, and robust assay for the measurement of CYP3A induction in both rat and human cultured primary hepatocytes.


Address correspondence to: Dr. Deborah A. Nicoll-Griffith, Director, Medicinal Chemistry, Merck Frosst Centre for Therapeutic Research, P.O. Box 1005, Pointe-Claire-Dorval, Quebec H9R 4P8, Canada. E-mail: deborah_nicoll-griffith{at}merck.com




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
M. Grondin, F. Hamel, F. Sarhan, and D. A. Averill-Bates
Metabolic Activity of Cytochrome P450 Isoforms in Hepatocytes Cryopreserved with Wheat Protein Extract
Drug Metab. Dispos., October 1, 2008; 36(10): 2121 - 2129.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Sudsakorn, J. Skell, D. A. Williams, T. J. O'Shea, and H. Liu
Evaluation of 3-O-Methylfluorescein as a Selective Fluorometric Substrate for CYP2C19 in Human Liver Microsomes
Drug Metab. Dispos., June 1, 2007; 35(6): 841 - 847.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. Michaud, J. Naud, J. Chouinard, F. Desy, F. A. Leblond, K. Desbiens, A. Bonnardeaux, and V. Pichette
Role of Parathyroid Hormone in the Downregulation of Liver Cytochrome P450 in Chronic Renal Failure
J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3041 - 3048.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. K. H. Chang, J. Chen, and X. W. Teng
DISTINCT ROLE OF BILOBALIDE AND GINKGOLIDE A IN THE MODULATION OF RAT CYP2B1 AND CYP3A23 GENE EXPRESSION BY GINKGO BILOBA EXTRACT IN CULTURED HEPATOCYTES
Drug Metab. Dispos., February 1, 2006; 34(2): 234 - 242.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.